Sensorion Announces Two Presentations at AAO-HNSF 2019 in New Orleans
17 Septembre 2019 - 7:30AM
Business Wire
- Clinical data demonstrating lack of sedation or cognitive
impairment by SENS-111 (Seliforant)
- Preclinical data on circulating prestin levels in a model of
mild noise-induced hearing loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a
pioneering clinical-stage biopharmaceutical company which
specializes in the development of novel therapies to restore, treat
and prevent inner ear diseases such as hearing loss, tinnitus and
vertigo, has contributed two presentations in the scientific poster
session at the 2019 Annual Meeting of the American Academy of
Otolaryngology, Head and Neck Surgery/Foundation (AAO-HNSF) held in
New Orleans LA, the 15-18th of September, 2019.
The first poster is entitled “SENS-111 Maintains Cognitive
Functions in Healthy Volunteers in Contrast to Meclizine”. The
study has demonstrated that SENS-111 compared to placebo has no
sedative effects and consequences on vigilance, cognition and
working memory confirmed by both the VigTrack and Pepsy® tests
battery. The data is further confirmed by patients’ self-assessed
measures on the Stanford Sleepiness Scale (SSS). In contrast,
Meclizine 50mg has been demonstrated to negatively impact vigilance
and showed sedative effects. The most important and limiting side
effect of sedation is counterproductive to normal functioning and
the natural recovery process from vertigo occurring via central
compensation. The impact of these findings on the long-term
recovery from acute vertigo will need to be confirmed in clinical
trials.
The presentation “Plasma Prestin and Distortion Product
Otoacoustic Emission Correlations after Mild Noise-Induced Hearing
Loss” demonstrated a strong correlation between the amplitude loss
of Distortion Product OtoAcoustic Emissions (DPOAE) and changes in
circulating Prestin levels in an animal model of variable and mild
noise-induced hearing loss studied in collaboration with with Dr.
Kourosh Parham at UCONN Health.
These results expand the successful collaboration with the group
of Dr. Parham on the potential of the inner ear specific protein
Prestin as a circulating biomarker, with promising results from a
more severe model of noise-induced hearing loss published jointly
in the peer-reviewed journal Hearing Research earlier this year
(Parham, K et all: Noise-induced trauma produces a temporal pattern
of change in blood levels of the outer hair cell biomarker Prestin,
Hear Res, 371:98-104, 2019).
About Seliforant
Seliforant (formerly SENS-111) is the first representative
candidate of the histamine type 4 receptor antagonist class to be
tested for the symptomatic treatment of vertigo crises. Displaying
a neuromodulation effect of the sensorineural inner ear cell
function, Seliforant is a small molecule that can be taken orally
or via a standard injection, and is currently in a separate Phase 2
clinical trial, being conducted in the United States, Europe,
Israel and South Korea.
About Sensorion
Sensorion is a pioneering clinical-stage biopharmaceutical
company, which specializes in the development of novel therapies to
restore, treat and prevent inner ear diseases such as hearing loss,
vertigo and tinnitus. Our clinical-stage portfolio includes two
phase 2 products: Seliforant (SENS-111) under investigation for
acute unilateral vestibulopathy and Arazasetron (SENS-401) for
sudden sensorineural hearing loss (SSNHL). We have built a unique
R&D technology platform to expand our understanding of the
physiopathology and etiology of inner ear related diseases enabling
us to select the best targets and modalities for drug candidates.
We also identify biomarkers to improve diagnosis and treatment of
these underserved illnesses. Sensorion is launching in the second
half of 2019 two preclinical gene programs aiming to correct
hereditary monogenic forms of deafness including Usher Type 1 and
deafness caused by a mutation of the gene encoding for Otoferlin.
We are uniquely placed through our platforms and pipeline of
potential therapeutics to make a lasting positive impact on
hundreds of thousands of people with inner ear related disorders; a
significant global unmet need in medicine today.
www.sensorion-pharma.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
‘Document de référence’ registration document filed with the
‘Autorité des Marchés Financiers’ (AMF French Financial Market
Authority) on September 7th, 2017 under n°R.17-062 and to the
development of economic conditions, financial markets and the
markets in which Sensorion operates. The forward-looking statements
contained in this press release are also subject to risks not yet
known to Sensorion or not currently considered material by
Sensorion. The occurrence of all or part of such risks could cause
actual results, financial conditions, performance or achievements
of Sensorion to be materially different from such forward-looking
statements.
This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190916005890/en/
Sensorion Nawal Ouzren CEO contact@sensorion-pharma.com
Tel: +33 467 207 730 Catherine Leveau Finance & Financial
communication catherine.leveau@sensorion-pharma.com Tel: +33 467
207 730
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024